We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

75 hedge funds and large institutions have $328M invested in KalVista Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 20 increasing their positions, 18 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

41% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 17

11% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 18

10% more funds holding

Funds holding: 68 → 75 (+7)

5.1% more ownership

Funds ownership: 80.61% → 85.72% (+5.1%)

18% less capital invested

Capital invested by funds: $398M → $328M (-$70.4M)

43% less funds holding in top 10

Funds holding in top 10: 7 → 4 (-3)

Holders
75
Holders Change
+7
Holders Change %
+10.29%
% of All Funds
1.63%
Holding in Top 10
4
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-42.86%
% of All Funds
0.09%
New
24
Increased
20
Reduced
18
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$15.6M
2
EAM
Eventide Asset Management
Massachusetts
+$14.1M
3
DM
Deerfield Management
New York
+$13.3M
4
PAMU
Pictet Asset Management (UK)
United Kingdom
+$10.7M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.66M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$41.2M
2
VMI
VHCP Management III
New York
-$7.8M
3
VMI
VHCP Management II
New York
-$4.61M
4
Renaissance Technologies
Renaissance Technologies
New York
-$4.58M
5
SHI
SV Health Investors
Massachusetts
-$2.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
26
Squarepoint
New York
$1.58M +$1.67M +71,244 New
Neuberger Berman Group
27
Neuberger Berman Group
New York
$1.43M +$725K +30,900 +92%
N
28
Nuveen
North Carolina
$1.37M +$1.45M +61,906 New
WMSA
29
Weiss Multi-Strategy Advisers
New York
$1.2M – – –
Bank of New York Mellon
30
Bank of New York Mellon
New York
$865K +$749K +31,958 +448%
JP Morgan Chase
31
JP Morgan Chase
New York
$806K -$581K -24,754 -40%
Wells Fargo
32
Wells Fargo
California
$791K +$25.9K +1,103 +3%
Charles Schwab
33
Charles Schwab
California
$605K +$640K +27,293 New
DCM
34
DAFNA Capital Management
California
$548K +$35.2K +1,500 +6%
AG
35
Algert Global
California
$546K +$189K +8,076 +49%
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
$521K -$576K -24,546 -51%
Barclays
37
Barclays
United Kingdom
$510K -$222K -9,482 -29%
Citadel Advisors
38
Citadel Advisors
Florida
$467K +$494K +21,072 New
Goldman Sachs
39
Goldman Sachs
New York
$463K -$396K -16,877 -45%
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$398K +$421K +17,971 New
Swiss National Bank
41
Swiss National Bank
Switzerland
$390K +$413K +17,600 New
SAM
42
Sectoral Asset Management
Quebec, Canada
$389K – – –
Two Sigma Investments
43
Two Sigma Investments
New York
$303K +$321K +13,696 New
VEA
44
Virtus ETF Advisers
New York
$297K +$314K +13,395 New
New York State Common Retirement Fund
45
New York State Common Retirement Fund
New York
$266K +$281K +12,000 New
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$237K +$251K +10,719 New
Two Sigma Advisers
47
Two Sigma Advisers
New York
$226K +$240K +10,222 New
California Public Employees Retirement System
48
California Public Employees Retirement System
California
$225K +$238K +10,153 New
Millennium Management
49
Millennium Management
New York
$219K -$2.03M -86,575 -90%
Man Group
50
Man Group
United Kingdom
$208K – – –
1
2
3 4

KALV Hedge Fund Activity: Q2 2019 in Review

75 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q2 2019, worth a combined $328M — down 18% from $398M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new KALV positions and 17 closed out — a net gain of 7 holders — while 20 added to existing stakes and 18 trimmed.

The largest buyer was BlackRock, adding an estimated $15.6M. The largest seller was RA Capital Management, exiting entirely with an estimated $41.2M sold.

  • 75 institutional investors held KalVista Pharmaceuticals (KALV) as of Q2 2019, up from 68 in Q1 2019.
  • Funds reported $328M of KalVista Pharmaceuticals stock for Q2 2019, down 18% quarter-over-quarter.
  • 24 funds opened new KalVista Pharmaceuticals positions in Q2 2019 and 17 closed out, a net change of +7 holders.
  • The largest KalVista Pharmaceuticals buyer in Q2 2019 was BlackRock, an estimated $15.6M added.
  • The largest KalVista Pharmaceuticals seller in Q2 2019 was RA Capital Management, an estimated $41.2M sold.

Based on aggregated 13F filings for Q2 2019.